IP Library Granted Patent US 8,252,745
Granted Patent B2
US 8,252,745 · App. 13/269,527 · Granted Aug 28, 2012

Methods for treatment of headaches by administration of oxytocin

Assignees: The Board of Trustees of the Leland Stanford Junior University; Trigemina, Inc.; HealthPartners Research Foundation
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,252,745
App. No.
13/269,527
Granted
Aug 28, 2012
Kind
B2
Abstract

The present invention relates to methods for the treatment of headache and headache disorders. The methods comprise administration of an oxytocin peptide for the treatment of primary and secondary headaches or trigeminal neuralgia.

Claims (15)

1. A method of treating chronic head or facial pain associated with the trigeminal nerve in an individual in need thereof comprising intranasally administering an effective dose of an oxytocin peptide, wherein the head or facial pain arises from trigeminal neuralgia.

2. The method according to claim 1 , wherein the oxytocin peptide is administered to the lower two thirds of the nasal cavity.

3. The method according to claim 1 , wherein the oxytocin peptide is administered as a pharmaceutical composition.

4. The method according to claim 3 , wherein the pharmaceutical composition further comprises at least one additional active agent.

5. The method according to claim 3 , wherein the pharmaceutical composition further comprises nociceptin/orphanin FQ.

6. The method according to claim 3 , wherein the pharmaceutical composition further comprises an effective therapeutic amount of a vasoconstrictor.

7. The method according to claim 3 , wherein the pharmaceutical composition further comprises one or more pharmaceutically acceptable excipients, adjuvants, diluents or stabilizers.

8. The method according to claim 3 , wherein the pharmaceutical composition further comprises at least one protease inhibitor or at least one absorption enhancer.

9. The method according to claim 3 , wherein the pharmaceutical composition further comprises at least one protease inhibitor and at least one absorption enhancer.

10. The method according to claim 1 , wherein the effective dose is about 0.1 IU to about 150 IU.

11. The method according to claim 1 , wherein the effective dose is about 4 IU to about 24 IU.

12. The method according to claim 1 , wherein administration results in reduction of a pain rating on the VAS of 30% or more.

13. The method according to claim 1 , wherein the effective dose is about 1 IU to about 100 IU.

14. The method according to claim 1 , wherein the effective dose is about 10 IU to about 80 IU.

15. The method according to claim 3 , wherein the pharmaceutical composition is administered as a powder, a gel, a film, an ointment, a liquid, a suspension, a cream or a bioadhesive.

Assignments (4)
MERGER Recorded Dec 19, 2012
From: HEALTHPARTNERS RESEARCH FOUNDATION
To: HEALTHPARTNERS RESEARCH & EDUCATION
Reel/Frame 029502/0140 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 9, 2011
From: YEOMANS, DAVID C.; ANGST, MARTIN S.
To: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
Reel/Frame 027201/0324 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 9, 2011
From: JACOBS, DANIEL I.
To: TRIGEMINA, INC.
Reel/Frame 027202/0040 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 9, 2011
From: FREY, WILLIAM H., II
To: HEALTHPARTNERS RESEARCH FOUNDATION
Reel/Frame 027202/0083 →
Continuity (5)
Continuation 12210866 · Sep 15, 2008
Continuation 11511997 · Aug 28, 2006
Provisional Application 60711950 · Aug 26, 2005
Provisional Application 60794004 · Apr 21, 2006
Related Publication 20120028898A1 · Feb 2, 2012